PhOx-430 is under clinical development by Phost’IN and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PhOx-430’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PhOx-430 is under development for the treatment of glioblastoma multiforme, HER2- breast cancer and triple negative breast cancer. They act by targeting cancer cell’s glycosylation and wreck tumor progression by unblocking anti-cancer immune response. It is administered through oral route.
Phost’IN is a biopharmaceutical company that focused on the discovery and development of N-glycosylation inhibitors for the treatment of cancers and other major diseases. It develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism that aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors. The company’s first candidate PhO430, which is in the preclinical last stage developing for the treatment of aggressive solid tumors, including rare cancers without satisfying curative treatment, such as Triple Negative Breast Cancers and Glioblastomas. Phost’IN is headquartered in Montpellier, France.
For a complete picture of PhOx-430’s drug-specific PTSR and LoA scores, buy the report here.